logo-loader
Genprex, Inc.

Genprex boss Rodney Varner trumpets gene therapy company’s recent achievements

Varner said “we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research"

Genprex, Inc. - Genprex boss Rodney Varner trumpets gene therapy company’s recent achievements
He added: “These accomplishments have set the stage for us to continue on our path of growth and expansion"

Genprex Inc’s (NASDAQ:GNPX) chairman and chief executive, Rodney Varner has trumpeted the gene therapy company’s recent achievements, noting that it has completed part of its overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex immunogene therapy, to commercialization.

In a statement on Tuesday, Varner said: “Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initiatives.”

He added: “These accomplishments have set the stage for us to continue on our path of growth and expansion, enabling our efforts to bring our drug candidate to market for lung cancer patients who cannot benefit from today’s therapies.”

The recent achievements are outlined in the company’s newly launched, interactive corporate timeline, which can be found on Genprex’s website.

Contact the author at [email protected]

Quick facts: Genprex, Inc.

Price: 0.2699 USD

Market: NASDAQ
Market Cap: $5.13 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex Inc making progress on branding for its lead cancer therapy, Oncoprex

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the biotech has initiated the first phase of branding for its lead drug candidate, Oncoprex, an immunogene therapy to treat non-small cell lung cancer. Varner says the Texas-based company has completed the creation and submission of...

on 6/8/19

2 min read